About the Webinar

Watch our exclusive webinar to see how cutting-edge AI is transforming screening and ligand identification in drug discovery!

In this webinar, our expert speakers, Benedikt Bauer PhD (Group Leader, In Silico R&D) and Ghislaine Marchand PhD (Group Leader, Biophysics), explore AI/ML technologies and how they have been applied during hit discovery to reduce cost, enhance speed and decrease risk. 

Key Insights

  • Understand how AI/ML technologies are integrated into ASMS workflows
  • Evaluate the impact of AI/ML-driven enrichment on screening efficiency
  • Gain knowledge of real-world application of AI/ML in hit discovery
     

Meet the Speakers:

Benedikt Bauer 2

Benedikt Bauer PhD

Group Leader, In Silico R&D

Latest update: September 2025

Biography

Benedikt Bauer leads a multidisciplinary data science group at Evotec Hamburg, driving the design and implementation of advanced analytics and machine learning models integrated into operational workflows. Since joining Evotec close to a decade ago, Benedikt has shaped various data related aspects of the company, from data management over data engineering to data science. His primary focus is on coordinating closely with biologists to identify scientific challenges where data science can deliver meaningful impact – bridging experimental insights with computational innovation. 

Ghislaine

Ghislaine Marchand PhD

Group Leader, Biophysics

Latest update: September 2025

Biography

Ghislaine Marchand leads the biophysics group at Evotec Toulouse, bringing over 25 years of expertise in the pharmaceutical industry. A trained pharmacist, she began her career at Sanofi, where she held various R&D positions spanning pharmacokinetics, anti-infective research and high-throughput screening. Since joining Evotec, Ghislaine has been at the forefront of biophysics innovation, overseeing a broad spectrum of technologies. Her team leverages key molecular interaction platforms such as surface plasmon resonance, microscale thermophoresis and differential scanning fluorimetry, alongside advanced mass spectrometry (MS)-based methods including affinity selection-MS, intact MS, peptide RapidFire-MS (RFMS), native MS and RFMS for both binding and functional assays. 

If the webinar has not loaded above, please click the link here.